SCM
NRIX icon

Suvretta Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Suvretta Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-280,760
Closed -$2.21M – 93
2023
Q3 		$2.21M Hold
280,760
– – 0.12% 61
2023
Q2 		$2.8M Buy
+280,760
New +$2.86M 0.15% 67

Other funds holding NRIX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Suvretta Capital Management's NRIX Position: Q4 2023 in Review

Suvretta Capital Management sold out of Nurix Therapeutics (NRIX) in Q4 2023, closing a stake of 280,760 shares — an estimated $2.21M sold.

Suvretta Capital Management first reported a position in NRIX in Q2 2023 and held it in 2 quarters. The position peaked at $2.8M in Q2 2023. 130 funds tracked by Wall St. Rank hold NRIX as of Q4 2023.

  • Suvretta Capital Management reported no remaining Nurix Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Suvretta Capital Management sold 280,760 Nurix Therapeutics shares in Q4 2023, an estimated $2.21M.
  • Suvretta Capital Management first reported a position in Nurix Therapeutics in Q2 2023 and held it in 2 quarters.
  • Suvretta Capital Management's Nurix Therapeutics position peaked at $2.8M in Q2 2023.
  • 130 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2023.

Based on Suvretta Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.